Parnax Lab

Who are the top shareholders of the Parnax Lab?

The top shareholders of Parnax Lab include promoters, with Binoy Baiju Shah holding the largest individual stake at 11.92%. Individual investors own 24.73% of the shares, while the highest public shareholder is Suman Gupta at 1.62; there are no mutual funds or foreign institutional investors involved.

The top shareholders of Parnax Lab primarily consist of promoters, with Binoy Baiju Shah holding the highest individual stake at 11.92%. Additionally, individual investors collectively hold 24.73% of the shares. Notably, there are no mutual funds or foreign institutional investors (FIIs) currently holding shares in the company. The highest public shareholder is Suman Gupta, who holds 1.62%.

Who are in the management team of Parnax Lab?

As of March 2022, the management team of Parnax Lab includes Prakash M Shah (CEO), Baiju M Shah (CFO), and several directors, including Vindyak B Desai, T V Anantharaman, and Yogesh Varia, along with Company Secretary Preet Vijay Kukreja. Each member contributes to the company's governance and operations.

As of March 2022, the management team of Parnax Lab includes the following individuals:<BR><BR>1. Vindyak B Desai - Independent Director<BR>2. Prakash M Shah - Director & Chief Executive Officer<BR>3. Baiju M Shah - Managing Director & Chief Financial Officer<BR>4. Ami M Shah - Director<BR>5. T V Anantharaman - Independent Director<BR>6. Yogesh Varia - Independent Director<BR>7. Preet Vijay Kukreja - Company Secretary & Compliance Officer<BR><BR>Each member plays a distinct role within the company's governance and operational structure.

What does Parnax Lab do?

Parnax Lab Ltd is a Micro Cap company that manufactures and exports pharmaceutical formulations. As of March 2025, it reported net sales of 49 Cr and a net profit of 3 Cr, with a market cap of Rs 125 Cr.

Overview:<BR>Parnax Lab Ltd is engaged in the manufacturing and export of pharmaceutical formulations within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History:<BR>Parnax Lab Ltd was incorporated in August 1982 and was formerly known as Krishna Deep Trade & Investment Ltd until it changed its name on July 19, 2012. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 49 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 3 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 125 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 11.00<BR>- Industry P/E: 30<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.84<BR>- Return on Equity: 13.86%<BR>- Price to Book: 1.49<BR><BR>Contact Details:<BR>Address: Gala 114 Bldg No 8, Jogani Ind Complex Chunabhatti Mumbai Maharashtra : 400022<BR>Tel: 91-022-6825 2525<BR>Email: info@naxparlab.com<BR>Website: http://www.naxparlab.com

Has Parnax Lab declared dividend?

No Dividend History Available

Who are the peers of the Parnax Lab?

Parnax Lab's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. In terms of management risk, growth, and capital structure, Parnax Lab ranks below average compared to its peers, with a 1-year return of 11.79%.

Peers: The peers of Parnax Lab are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Source Natural, Bharat Immunolog, Samrat Pharma, Mercury Labs, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Samrat Pharma, while Good management risk is found at Divi's Lab., Source Natural, and the rest. Below Average management risk is noted for Parnax Lab, Bharat Immunolog, and Ajooni Biotech. In terms of Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is noted for Parnax Lab. Below Average growth is present at Divi's Lab., Torrent Pharma, Source Natural, Bharat Immunolog, and Ajooni Biotech. Excellent capital structure is exhibited by Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Mercury Labs, while Good capital structure is found at Torrent Pharma and Samrat Pharma, and Below Average capital structure is noted for Parnax Lab and Bharat Immunolog.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while Bharat Immunolog has the lowest at -9.56%. Parnax Lab's own 1-year return is 11.79%, which is higher than Bharat Immunolog's but lower than Divi's Lab.'s. Additionally, the peers with negative six-month returns include Parnax Lab, Source Natural, Mercury Labs, and Bharat Immunolog.

What is the technical trend for Parnax Lab?

As of May 27, 2025, Parnax Lab's technical trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, despite some bullish indicators on the weekly chart.

As of 27 May 2025, the technical trend for Parnax Lab has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands show a bullish stance on the weekly chart but are mildly bearish on the monthly chart. Moving averages are mildly bearish on the daily timeframe. The KST is mildly bullish weekly but mildly bearish monthly, and Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from the MACD and Bollinger Bands.

How big is Parnax Lab?

As of 24th July, Parnax Lab Ltd has a market capitalization of 149.00 Cr, with recent net sales of 187.74 Cr and a net profit of 11.52 Cr. The balance sheet for March 2024 shows shareholder's funds of 71.57 Cr and total assets of 188.77 Cr.

As of 24th July, Parnax Lab Ltd has a market capitalization of 149.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Parnax Lab reported Net Sales of 187.74 Cr and a Net Profit of 11.52 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 71.57 Cr and Total Assets of 188.77 Cr.

Is Parnax Lab overvalued or undervalued?

As of November 10, 2025, Parnax Lab is considered an attractive investment opportunity due to its undervalued status with a PE ratio of 13.34 and strong financial ratios, despite a year-to-date stock decline of 25.27%.

As of 10 November 2025, Parnax Lab's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its stock. The company is currently considered undervalued, supported by a PE ratio of 13.34, an EV to EBITDA of 8.24, and a ROE of 13.86%. In comparison to its peers, Parnax Lab's valuation stands out against Elitecon International, which is deemed very expensive with a PE ratio of 359.8, and PTC India, which is classified as very attractive with a PE ratio of 7.89.<BR><BR>Despite recent stock performance showing a decline of 25.27% year-to-date compared to a 6.91% gain in the Sensex, Parnax Lab's strong financial ratios and improved valuation grade suggest that it may present a compelling investment opportunity. The company's solid fundamentals, including a PEG ratio of 2.54, further reinforce the notion that it is undervalued relative to its peers in the pharmaceuticals and biotechnology industry.

Are Parnax Lab latest results good or bad?

Parnax Lab's latest results show strong revenue growth of 17.27% QoQ and 29.45% YoY, reaching ₹62.60 crores, but profitability concerns arise as the operating profit margin has decreased to 12.89% and net profit declined 6.45% YoY. Overall, while sales performance is positive, challenges in cost management and profitability remain.

Parnax Lab's latest results present a mixed picture. On the positive side, the company achieved a significant revenue growth of 17.27% quarter-over-quarter (QoQ) and 29.45% year-over-year (YoY), reaching net sales of ₹62.60 crores. This marks the highest quarterly sales in the company's recent history, indicating strong market demand and successful product performance.<BR><BR>However, this revenue growth comes with concerns regarding profitability. The operating profit margin has contracted to 12.89%, down from 14.97% a year earlier, which raises questions about cost management and pricing power in a competitive environment. Additionally, while net profit increased by 11.01% QoQ to ₹3.63 crores, it saw a decline of 6.45% YoY, reflecting challenges in maintaining profitability despite rising sales.<BR><BR>Overall, while the revenue growth is commendable, the margin compression and declining net profit year-over-year suggest that the company is facing significant operational challenges. Investors may view the results as good in terms of sales performance but concerning regarding profitability and cost management.

How has been the historical performance of Parnax Lab?

Parnax Lab has shown steady growth in net sales and profitability, with net sales reaching 187.74 Cr in March 2025, up from 163.03 Cr in March 2022. Key financial metrics, including profit after tax and earnings per share, have also improved, reflecting a positive trend in overall performance.

Answer:<BR>The historical performance of Parnax Lab shows a steady growth in net sales and profitability over the years, culminating in the latest figures for March 2025.<BR><BR>Breakdown:<BR>Parnax Lab's net sales increased slightly to 187.74 Cr in March 2025 from 188.71 Cr in March 2024, showing a growth trend from 167.61 Cr in March 2023 and 163.03 Cr in March 2022. The total operating income mirrored this trend, reaching 187.74 Cr in March 2025. The total expenditure, excluding depreciation, decreased to 160.97 Cr in March 2025 from 165.17 Cr in March 2024, contributing to an operating profit (PBDIT) of 28.45 Cr, up from 24.36 Cr the previous year. Profit before tax also rose to 15.67 Cr in March 2025, compared to 12.05 Cr in March 2024, while profit after tax reached 11.54 Cr, an increase from 9.62 Cr. The earnings per share improved to 10.03 in March 2025 from 8.36 in March 2024. On the balance sheet, total assets stood at 189.82 Cr in March 2025, slightly down from 190.26 Cr in March 2024, with total liabilities also decreasing to 189.82 Cr from 190.26 Cr. The company maintained a book value per share of 72.35 in March 2025, up from 62.32 in March 2024. Cash flow from operating activities significantly improved to 32.00 Cr in March 2025 from 15.00 Cr in March 2024, indicating a positive cash flow trend.

When is the next results date for Parnax Lab Ltd?

The next results date for Parnax Lab Ltd is 13 February 2026.

The next results date for Parnax Lab Ltd is scheduled for 13 February 2026.

Should I buy, sell or hold Parnax Lab Ltd?

Which are the latest news on Parnax Lab?

Why is Parnax Lab Ltd falling/rising?

As of 11-Feb, Parnax Lab Ltd's stock price is declining, currently at 118.50, reflecting a 2.99% decrease. The stock has underperformed against the Sensex and shows short-term weakness despite increased investor participation.

As of 11-Feb, Parnax Lab Ltd's stock price is falling, currently at 118.50, which reflects a decrease of 3.65 or 2.99%. The stock has been underperforming compared to the benchmark Sensex, which has gained 0.50% over the past week, while Parnax Lab Ltd has declined by 4.16%. Additionally, the stock has shown a negative trend over the last two days, with a total drop of 4.28%. <BR><BR>Today, the stock opened with a loss of 3.23% and reached an intraday low of Rs 118.2. Although the stock is trading above its 20-day and 200-day moving averages, it is below the 5-day, 50-day, and 100-day moving averages, indicating a short-term weakness. Furthermore, despite a rise in investor participation, with delivery volume increasing by 75.26% against the 5-day average, the overall performance today has underperformed the sector by 3.25%. <BR><BR>In summary, the combination of recent consecutive declines, underperformance against the benchmark, and a negative opening today contributes to the falling stock price of Parnax Lab Ltd.